Efficacy and tolerability of first-line anti-HER2 therapy for HER2+ advanced breast cancer: A single-centre real-world experience.

e13014Background: Taxanes+Trastuzumab+Pertuzumab (THP) is standard-of-care 1st line treatment for HER2 positive advanced breast cancer (ABC) based on the CLEOPATRA trial and Pertuzumab is available in the UK as of April 2013. However, there are concerns about the applicability of these findings in the real world. We evaluated clinical benefit rate (CBR), overall response rate (ORR), progression-free survival (PFS), overall survival (OS) and tolerability of 1st line anti-HER2 treatment in our patients and compared outcomes across different anti-HER2 regimens. Methods: We retrospectively identified 241 patients receiving 1st line for HER2+ ABC at our Institution between April 2011 and August 2016. Demographics, disease characteristics, (neo-)adjuvant treatments, disease sites, toxicities, treatment delays and responses were recorded. Fisher’s exact test or chi-squared method were used as appropriate, along with Cox regression to explore differences among groups. Results: In our analysis median follow-up was...